Showing 1 - 10 of 27 Other
Multicenter, Registry Study of Avance® Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair

Status: Enrolling

Investigator: Warren Ellsworth

Study Coordinator: Adrienne New

Phone: 713.441.3250

This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >

A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care (ISABELA1)

Status: Enrolling

Investigator: Sandeep Sahay

Study Coordinator: Taniqua Warren

Phone: 713.363.9280

The main purpose of this study is to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general. The study will also investigate how well GLPG1690 is tolerated (for example if you get an ... Read more >

A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy

Status: Enrolling

Investigator: Deepa Gotur

Study Coordinator: Alexandra Villanueva

Phone: 713.441.3879

The purpose of this research study is to see how safe and effective the use of Technegas imaging is in lung imaging. Technegas is an investigational aerosol imaging agent that you inhale that makes the lungs show up during a nuclear medicine ven ... Read more >

A Multicenter, Registry Study of Avance® Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair

Status: Enrolling

Investigator: Aldona Spiegel

Study Coordinator: Adrienne New

Phone: 713.441.3250

This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >

A Prospective, Randomized, Multi-center, Single-Blinded, Placebo-Controlled, 3-Arm Clinical Study to Assess the Efficacy and Safety of Vibrant Capsule, for the Treatment of Chronic Idiopathic Constipation

Status: Enrolling

Investigator: Eamonn Quigley

Study Coordinator: Alejandro De La Torre

Phone: 713.441.6396

The study is a prospective, randomized, multicenter, adaptive design, single blinded, placebo-controlled study, to evaluate the efficacy and safety of Vibrant Capsule vs. placebo in relieving constipation in subjects with Chronic Idiopathic Cons ... Read more >

A Registry for Patients Taking Uptravi (SPHERE)

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Royanne Holy

Phone: 713.363.7536

This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into t ... Read more >

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE ) (TRAVERSE)

Status: Enrolling

Investigator: David Mobley

Study Coordinator: Brittany Foerster

Phone: 281.276.3053

This is a blinded and placebo-controlled study of topical testosterone replacement therapy (TRT) in symptomatic hypogonadal men with increased risk for cardiovascular (CV) disease. ... Read more >

A011-09 PULSAR A Phase 2 Study of Sotatercept for the Treatment of PAH

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Jennifer Lee

Phone: 713.363.7537

Study A011-09 is a Phase 2, double-blind, randomized, placebo-controlled, multicenter, parallel-group study to determine the efficacy and safety of sotatercept (ACE-011) plus standard of care (SOC) versus placebo plus SOC in adults with pulmonar ... Read more >

ADAPT - A Patient Registry of the Real-world Use of Orenitram®

Status: Enrolling

Investigator: Sandeep Sahay

Study Coordinator: Taniqua Warren

Phone: 713.363.9280

This prospective, observational, multicenter, patient registry will follow patients who are receiving treatment with Orenitram for the treatment of PAH for up to 78 weeks from Orenitram initiation ... Read more >

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis (OPAL)

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Beatriz Efron

Phone: 713.363.8890

The purpose of this study is to compare the incidence of lymphoma in adult participants with moderate-to-severe ulcerative colitis who are treated with Simponi versus those treated with thiopurines. ... Read more >

Cook SUI IND

Status: Open Not Enrolling

Investigator: Danielle Antosh

Study Coordinator: Alexandra Villanueva

Phone: 713.441.3879

This randomized, double-blind, placebo-controlled, multi-center, confirmatory study will evaluate the efficacy and safety of Cook MyoSite Incorporated Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR) compared to a placebo ... Read more >

Corrona Inflammatory Bowel Disease (IBD) Registry

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Caroline Perry

Phone: 346.238.0307

This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for IBD in a cohort of patients cared for by gastroenterologists across North America. Second ... Read more >

CXA-10-2302 Study in Subjects With Pulmonary Arterial Hypertension

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Jennifer Lee

Phone: 713.363.7537

This is a Phase 2, multicenter, open-label extension (OLE) of study CXA-10-301, to evaluate the long term safety and efficacy of daily dosing of CXA-10. The study will be performed in approximately 50 study centers across the United States an ... Read more >

Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2)

Status: Enrolling

Investigator: Monica Morgan

Study Coordinator: Michelle Guthrie

Phone: 713.441.6564

Treatment ... Read more >

GORE® TAG® Thoracic Branch Endoprosthesis

Status: Enrolling

Investigator: Marvin Atkins

Study Coordinator: Kim Donlon

Phone: 713.441.9394

This study is a prospective, multicenter, non-randomized single-arm study to assess the feasibility of the treatment of DeBakey Type I/II aortic dissections with the GORE® TAG® Thoracic Branch Endoprosthesis system. ... Read more >

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry (IPF/ILD-PRO)

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Jennifer Lee

Phone: 713.363.7537

This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applie ... Read more >

MarrowStim

Status: Open Not Enrolling

Investigator: Eric Peden

Study Coordinator: Kim Donlon

Phone: 713.441.9394

This trial will evaluate the safety and efficacy of concentrated bone marrow aspirate (cBMA) to prevent or delay major amputation and/or death in subjects with critical limb ischemia (CLI) due to severe peripheral arterial disease (PAD). ... Read more >

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso (BREEZE)

Status: Enrolling

Investigator: Sandeep Sahay

Study Coordinator: Jennifer Lee

Phone: 713.363.7537

United Therapeutics Corporation (UTC) is developing a combination drug-device product which is comprised of a dry powder formulation of Treprostinil Inhalation Powder (TreT) and a small, portable, dry powder inhaler. In this Phase 1b safety and ... Read more >

OPsumit USers Registry (OPUS)

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Taniqua Warren

Phone: 713.363.9280

Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-m ... Read more >

PIANO

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Caroline Perry

Phone: 346.238.0307

A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease study is being conducted at the University of California San Francisco and 30 other sites around the United States who are part ... Read more >

PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Taniqua Warren

Phone: 713.363.9280

This is a multicenter double-blind, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to 80 years of age with PAH. The study will be performed in ... Read more >

SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry (SECURE)

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Caroline Perry

Phone: 346.238.0307

The purpose of this study is to monitor safety outcomes of patients who have taken Cimzia® as compared to a non- Cimzia® control population. The SECURE Registry's target enrollment is 3045 patients and its objective is to monitor patients for ap ... Read more >

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension standard of care or PAH-specific background therapy in subjects with World Health Organization Group 1 PAH

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Royanne Holy

Phone: 713.363.7536

Study ROR-PH-301 is a multicenter, randomized, double-blind, placebo-controlled study. Subjects who meet entry criteria will be randomly allocated 1:1 to receive ralinepag or placebo, in addition to their standard of care or PAH-specific backgro ... Read more >

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Royanne Holy

Phone: 713.363.7536

Study ROR-PH-303 is a multicenter, open-label extension (OLE) study for subjects with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag and who qualify for entry based upon participation in the prior study. S ... Read more >

Supraspinal Targets in Voiding Dysfunction

Status: Enrolling

Investigator: Rose Khavari

Study Coordinator: Hamida Rajab

Phone: 713.363.9154

Difficulty in bladder emptying (Voiding dysfunction,VD) is a costly urinary condition that leads to urinary tract infections/stones, sepsis, bladder loss, and permanent kidney damage. VD can be present in patients with or without neurologic/brai ... Read more >

The MARE Study

Status: Enrolling

Investigator: Neal Kleiman

Study Coordinator: Patricia Brinegar

Phone: 713.441.3506

The purpose of this study is to determine the incidence and predictors of high degree or complete atrioventricular block (AVB) (paroxysmal or persistent) in patients with new-onset persistent left bundle branch block (NOP-LBBB) following transca ... Read more >

The MENDSII Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure (MENDSII)

Status: Enrolling

Investigator: Joshua Swan

Study Coordinator: Alejandro De La Torre

Phone: 713.441.6396

Ventilated ICU patients frequently have sepsis and the majority have delirium, a form of brain dysfunction that is an independent predictor of increased risk of dying, length of stay, costs, and prolonged cognitive impairment in survivors. Unive ... Read more >

Live Chat Available